When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
© Chonnam Medical Journal, 2023..
Long-acting β2-agonist (LABA)/long-acting muscarinic-antagonist (LAMA) dual therapy has been found to be more effective than LAMA monotherapy in the treatment of chronic obstructive pulmonary disease (COPD). However, among patients with group B or D COPD, the characteristics of patients for whom LABA/LAMA dual therapy is superior to LAMA monotherapy in minimizing acute exacerbations remain unknown. With data from a prospective COPD cohort, subgroup analyses were conducted to determine whether LABA/LAMA dual therapy was superior to LAMA monotherapy in reducing the rate of acute exacerbations in group B and D COPD patients. Group B and D COPD patients taking LAMA or LABA/LAMA were enrolled according to the 2022 Global initiative for Chronic Obstructive Pulmonary Disease guidelines. A total of 737 patients were included in this study: 600 with group B COPD and 137 with group D COPD. Compared with patients taking LAMA monotherapy, those taking LABA/LAMA had a significantly lower incidence of acute exacerbations over 1 year. In the subgroup of patients ≥70 years old, there was a significantly lower risk of severe COPD exacerbations among group B patients taking LABA/LAMA than among those taking LAMA monotherapy (odds ratio [OR], 0.258; 95% confidence interval [CI], 0.095-0.703). In contrast, in the subgroup of group D patients with COPD Assessment Test scores ≥25, compared with LAMA monotherapy, LABA/LAMA treatment was associated with lower risk of severe COPD exacerbations (OR, 0.115; 95% CI, 0.018-0.749). The combination of LABA and LAMA was found to be superior to LAMA monotherapy, especially for treating older adults with group B COPD, as well as for group D patients with severe symptoms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Chonnam medical journal - 59(2023), 3 vom: 28. Sept., Seite 180-187 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shin, Hong-Joon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bronchodilator Agents |
|---|
| Anmerkungen: |
Date Revised 20.10.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4068/cmj.2023.59.3.180 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363334874 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363334874 | ||
| 003 | DE-627 | ||
| 005 | 20231226211030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4068/cmj.2023.59.3.180 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363334874 | ||
| 035 | |a (NLM)37840676 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shin, Hong-Joon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © Chonnam Medical Journal, 2023. | ||
| 520 | |a Long-acting β2-agonist (LABA)/long-acting muscarinic-antagonist (LAMA) dual therapy has been found to be more effective than LAMA monotherapy in the treatment of chronic obstructive pulmonary disease (COPD). However, among patients with group B or D COPD, the characteristics of patients for whom LABA/LAMA dual therapy is superior to LAMA monotherapy in minimizing acute exacerbations remain unknown. With data from a prospective COPD cohort, subgroup analyses were conducted to determine whether LABA/LAMA dual therapy was superior to LAMA monotherapy in reducing the rate of acute exacerbations in group B and D COPD patients. Group B and D COPD patients taking LAMA or LABA/LAMA were enrolled according to the 2022 Global initiative for Chronic Obstructive Pulmonary Disease guidelines. A total of 737 patients were included in this study: 600 with group B COPD and 137 with group D COPD. Compared with patients taking LAMA monotherapy, those taking LABA/LAMA had a significantly lower incidence of acute exacerbations over 1 year. In the subgroup of patients ≥70 years old, there was a significantly lower risk of severe COPD exacerbations among group B patients taking LABA/LAMA than among those taking LAMA monotherapy (odds ratio [OR], 0.258; 95% confidence interval [CI], 0.095-0.703). In contrast, in the subgroup of group D patients with COPD Assessment Test scores ≥25, compared with LAMA monotherapy, LABA/LAMA treatment was associated with lower risk of severe COPD exacerbations (OR, 0.115; 95% CI, 0.018-0.749). The combination of LABA and LAMA was found to be superior to LAMA monotherapy, especially for treating older adults with group B COPD, as well as for group D patients with severe symptoms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bronchodilator Agents | |
| 650 | 4 | |a Chronic Obstructive Pulmonary Disease | |
| 650 | 4 | |a Combined Modality Therapy | |
| 700 | 1 | |a Kim, Yu-Il |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Youlim |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chang Youl |e verfasserin |4 aut | |
| 700 | 1 | |a Ra, Seung Won |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Ji-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Ki-Suck |e verfasserin |4 aut | |
| 700 | 1 | |a Yoo, Kwang Ha |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Kyeong-Cheol |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Sung-Chul |e verfasserin |4 aut | |
| 700 | 0 | |a KOCOSS Cohort Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chonnam medical journal |d 2012 |g 59(2023), 3 vom: 28. Sept., Seite 180-187 |w (DE-627)NLM217647766 |x 2233-7385 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2023 |g number:3 |g day:28 |g month:09 |g pages:180-187 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4068/cmj.2023.59.3.180 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2023 |e 3 |b 28 |c 09 |h 180-187 | ||